JP7580800B2 - 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法 - Google Patents

可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法 Download PDF

Info

Publication number
JP7580800B2
JP7580800B2 JP2021502769A JP2021502769A JP7580800B2 JP 7580800 B2 JP7580800 B2 JP 7580800B2 JP 2021502769 A JP2021502769 A JP 2021502769A JP 2021502769 A JP2021502769 A JP 2021502769A JP 7580800 B2 JP7580800 B2 JP 7580800B2
Authority
JP
Japan
Prior art keywords
lifr
polypeptide
lif
soluble
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531002A (ja
JPWO2020018932A5 (https=
JP2021531002A5 (https=
Inventor
アレクサンダー ハンター、ショーン
ジェニファー アール． コクラン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2021531002A publication Critical patent/JP2021531002A/ja
Publication of JPWO2020018932A5 publication Critical patent/JPWO2020018932A5/ja
Publication of JP2021531002A5 publication Critical patent/JP2021531002A5/ja
Priority to JP2024098901A priority Critical patent/JP2024138287A/ja
Application granted granted Critical
Publication of JP7580800B2 publication Critical patent/JP7580800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021502769A 2018-07-20 2019-07-19 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法 Active JP7580800B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024098901A JP2024138287A (ja) 2018-07-20 2024-06-19 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701399P 2018-07-20 2018-07-20
US62/701,399 2018-07-20
PCT/US2019/042648 WO2020018932A1 (en) 2018-07-20 2019-07-19 Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024098901A Division JP2024138287A (ja) 2018-07-20 2024-06-19 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法

Publications (4)

Publication Number Publication Date
JP2021531002A JP2021531002A (ja) 2021-11-18
JPWO2020018932A5 JPWO2020018932A5 (https=) 2022-07-26
JP2021531002A5 JP2021531002A5 (https=) 2022-07-26
JP7580800B2 true JP7580800B2 (ja) 2024-11-12

Family

ID=69164867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502769A Active JP7580800B2 (ja) 2018-07-20 2019-07-19 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法
JP2024098901A Pending JP2024138287A (ja) 2018-07-20 2024-06-19 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024098901A Pending JP2024138287A (ja) 2018-07-20 2024-06-19 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法

Country Status (8)

Country Link
US (1) US12049490B2 (https=)
EP (1) EP3823983A4 (https=)
JP (2) JP7580800B2 (https=)
KR (1) KR102917499B1 (https=)
CN (1) CN112673017A (https=)
AU (1) AU2019305086B2 (https=)
CA (1) CA3106679A1 (https=)
WO (1) WO2020018932A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006563A1 (en) * 2024-06-27 2026-01-02 Nvasc, Inc. Long-lasting lif proteins and formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2139504A1 (en) * 1992-07-01 1994-01-20 Nicos A. Nicola Leukaemia inhibitory factor-binding protein
AUPO632897A0 (en) * 1997-04-21 1997-05-15 Walter And Eliza Hall Institute Of Medical Research, The Novel chimeric molecules
EP1878745B1 (en) * 2005-04-22 2011-06-15 Keio University Humanin receptor or humanin-like polypeptide receptor
KR101235820B1 (ko) * 2012-02-17 2013-02-21 한국생명공학연구원 항암 표적치료제제 감수성 예측용 ｓｎｐ
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018029586A1 (en) * 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Eur. J. Biochem.，2002年，Vol.269，p.2716-2726
The EMBO Journal，1991年，Vol.10, No.10，p.2839-2848
The Journal of Biological Chemistry，2003年，Vol.278, No.18，p.16253-16261

Also Published As

Publication number Publication date
EP3823983A4 (en) 2022-05-18
EP3823983A1 (en) 2021-05-26
CA3106679A1 (en) 2020-01-23
AU2019305086B2 (en) 2024-11-28
KR20210032493A (ko) 2021-03-24
JP2021531002A (ja) 2021-11-18
US20210300992A1 (en) 2021-09-30
WO2020018932A1 (en) 2020-01-23
US12049490B2 (en) 2024-07-30
JP2024138287A (ja) 2024-10-08
AU2019305086A1 (en) 2021-02-18
CN112673017A (zh) 2021-04-16
KR102917499B1 (ko) 2026-01-26

Similar Documents

Publication Publication Date Title
JP7252278B2 (ja) 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
US20190016793A1 (en) Albumin binding domain fusion proteins
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
CN113840831A (zh) 医用ngf拮抗剂
AU2016213702B2 (en) Activatable binding polypeptides and methods of identification and use thereof
JP2018505675A (ja) 新規なｅｇｆｒ結合タンパク質
JP2024138287A (ja) 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法
DK2657252T3 (en) MODIFIED HUMAN TUMOR CANCER FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF AND METHOD OF PRODUCING THEREOF
JP7257680B2 (ja) 毛様体神経栄養因子受容体リガンド結合剤およびその使用方法
US12122839B2 (en) IFNGR binding synthetic cytokines and methods of use
US20230391891A1 (en) Il28a receptor binding synthetic cytokines and methods of use
RU2829812C2 (ru) Антагонисты ngf для медицинского использования

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241023

R150 Certificate of patent or registration of utility model

Ref document number: 7580800

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150